Thrombopoietin

Dragon is developing an engineered version of the naturally occurring human protein thrombopoietin, TPO. This protein is produced mainly by the liver and stimulates the production of blood platelets and bone marrow platelet progenitor (!!±pre-platelet!!L) cells. Platelets are critical to blood clotting and wound healing, and are often diminished in patients receiving cancer chemotherapy, or […]

Continue reading


Human Insulin

Dragon is developing an engineered version of insulin, a naturally occurring hormone produced by the pancreas. Insulin is critical for regulating the level of glucose in the blood and, since glucose is the primary energy source for the body, is essential for normal metabolism. A defect in insulin production, or an abnormal response to insulin, […]

Continue reading


Slow-Release EPO*

Industry analysts estimate the market for slow-release EPO at $5 billion per year, with application in the treatment of anemia in patients with kidney failure and cancer patients undergoing chemotherapy. In June 2000, Dragon acquired rights to a novel and patentable formulation for slow-release EPO by entering into a co-development agreement with Renapharm AB of […]

Continue reading